



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/731,231	12/07/2000	Karl Guegler	CL001007

CONFIRMATION NO. 8743

25748
CELERA GENOMICS CORP.
ATTN: ROBERT A. MILLMAN, PATENT DIRECTOR
45 WEST GUDE DRIVE
C2-4#20
ROCKVILLE, MD 20850

FORMALITIES LETTER



OC000000005840198

Date Mailed: 03/08/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

03/08/2001 MAILING 00000045 510970 09731231

FILED UNDER 37 CFR 1.53(b)

01	FC:101	710.00	CH
02	FC:105	130.00	CH
03	FC:102	240.00	CH
04	FC:103	54.00	CH

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).


- The statutory basic filing fee is missing.
Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$294.
 - \$54 for 3 total claims over 20.
 - \$240 for 3 independent claims over 3.
- The oath or declaration is missing.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 1134.
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the Patent and Trademark Office, such request in

accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GUEGLER et al

Serial No. 09/731,231

Filed: December 7, 2000

For: ISOLATED HUMAN KINASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING
HUMAN KINASE PROTEINS, AND USES
THEREOF

Art Unit:

Examiner:

Atty. Docket: CL001007

**SUBMISSION OF SEQUENCE LISTING
UNDER 37 C.F.R. § 1.821(a)**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), Applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing.

In the Specification:

Please enter the Sequence Listing between the specification and the claims of the above-identified application.

REMARKS

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.


In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

It is respectfully believed this application is now in condition for examination.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

CELERA GENOMICS

By: 

Robert A. Millman

Reg. No. 36,217

Date: May 1, 2001

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Attention: Application Branch

GUEGLER et al

Atty. Dkt. CL001007

Serial No. 09/731,231

MAY 01 2001

Filed: December 7, 2000

Date: May 1, 2001

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES
ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

Assistant Commissioner for Patents

Washington, D.C. 20231

The attached completes filing of the above-identified patent application:

- ☒ Signed Rule 63 Declaration alone OR
- ☐ Signed Declaration plus attached copy of originally filed specification/drawings.
- ☒ **NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED** form.
- ☐ Record and return the attached assignment.
- ☐ Priority is hereby claimed per Rule 55 & 35 USC119 based on prior foreign application(s) Nos.:
- | Application Nos. | Country | Filing Date |
|------------------|---------|-------------|
|------------------|---------|-------------|

respectively.

☐ This application is based on the following prior provisional application(s):

Application No.	Filing Date
-----------------	-------------

respectively and priority is hereby claimed therefrom.

Certified copy(ies) of foreign and/or provisional application(s): ☐ attached; ☐ already filed on _____
in U.S. Application Serial No. _____, filed on _____.

☐ The undersigned verifies that the above-identified application is identical to: filed _____, as amended on _____.

☐ This application is entitled to "Small entity" status. ☐ "Small entity" statement attached.

☒ Also attached: Preliminary Amendment; Sub of Computer Readable Sequence Listing Diskette and 102 pages of Paper Copy of Sequence Listing

Fees are attached as calculated below:

Basic filing fee		\$	710.00
Total Effective claims	23 - 20 = 3	x \$	18.00
Independent claims	6 - 3 = 3	x \$	80.00
If any proper multiple dependent claims now added for first time, add \$	(ignore improper)	\$	0.00
	FILING FEE	\$	1,004.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$ /1 month; \$ /2 months; \$ /3 months; \$ /4 months)		\$	0.00
Surcharge (\$130.00) if Declaration or filing fee first now submitted		\$	130.00
	FIRST SUBTOTAL	\$	1,134.00
If "small entity," enter half (1/2) of subtotal and subtract		-\$	0.00
	SECOND SUBTOTAL	\$	1,134.00
Assignment Recording Fee (\$)		\$	0.00
	TOTAL FEE CHARGED TO DEPOSIT ACCOUNT	\$	1,134.00

The Commissioner is hereby authorized to charge filing fees and credit **Deposit Account Number 50-0970**. Any future submission requiring an extension of time is hereby stated to include a petition for such time extension. The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this corporation) to our **Account No. 50-0970**. A duplicate copy of this sheet is attached.

CELERA GENOMICS Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Telephone: 240-453-3067
RAM/pdc

CELERA GENOMICS Corporation
By Atty: Robert A. Millman, Reg. #36,217

Signature: Robert A. Millman